ライフサイエンスコーパス: continuous intravenous infusion

1 us], and fluorouracil 2400 mg/m(2) as a 46-h continuous intravenous infusion).

2 tumomab was administered in 28-day cycles by continuous intravenous infusion.

3 doses of 0.05 to 0.25 mg/kg/h for 10 days by continuous intravenous infusion.

4 s of cytarabine (100 mg per square meter) by continuous intravenous infusion.

5 eneficial actions, especially when used as a continuous intravenous infusion.

6 administered (3 to 7 mg/kg/d for 7 days) by continuous intravenous infusion.

7 dependent manner following a bolus dose and continuous intravenous infusion.

8 reated with a 12-day course of tacrolimus by continuous intravenous infusion.

9 All treated patients received dopamine as a continuous intravenous infusion.

10 fore transplant at a dose of 0.04 mg/kg/d by continuous intravenous infusion.

11 shion with no intravenous fluids (n = 24), a continuous intravenous infusion (0.3 mL/hr) of 0.9% sali

12 intravenous infusion for 3 hrs followed by a continuous intravenous infusion (1 mL/kg/hr) of 5% hyper

13 receive rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other

14 sine were investigated in 13 patients during continuous intravenous infusion and boluses of adenosine

15 unilateral treatment and 11.1% that of daily continuous intravenous infusions and oral valganciclovir

16 ng strategies have been initiated, including continuous intravenous infusions and subcutaneous IL-15

17 rse events, which is currently explored by a continuous intravenous infusion approach.

18 s with active HCL were treated with 2-CdA by continuous intravenous infusion at 0.1 mg/kg/d for a tot

19 A course of cladribine constituted a 7-day continuous intravenous infusion at a dose of 0.1 mg/kg/d

20 2-CdA was administered by continuous intravenous infusion at a dose of 0.1 mg/kg/d

21 8, 15, and 22 and heparin coadministered by continuous intravenous infusion at a dose of 0.13 mg/kg

22 LOLA was given as continuous intravenous infusion at a dose of 30 g over 2

23 h or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before

24 Recombinant IL-2 9 x 10(6) IU/m2 daily by continuous intravenous infusion (c.i.v.) was given for 4

25 tereoisomer of leucovorin (LV) as a 132-hour continuous intravenous infusion (CIV) with cisplatin 100

26 senting levels I, II, and III) for 5 days by continuous intravenous infusion (CIV).

27 es were defined as paclitaxel 13.1 mg/m(2)/d continuous intravenous infusion (CIVI) for 4 days withou

28 nitially treated with paclitaxel 175 mg/m(2) continuous intravenous infusion (CIVI) over 3 hours.

29 ting doses of YM155 administered by 168-hour continuous intravenous infusion (CIVI).

30 d perhaps less toxic, when administered as a continuous intravenous infusion (CIVI).

31 tment consisted of topotecan 1.25 mg/m(2) by continuous intravenous infusion daily for 5 days and cyt

32 y 1 and fluorouracil 1,000 mg/m2/24 hours by continuous intravenous infusion day 1 through 4) or CP (

33 administering flavopiridol by a 24- to 72-h continuous intravenous infusion demonstrated no clinical

34 es free flavopiridol concentration and makes continuous intravenous infusion dosing ineffective.

35 platin (20 mg/m(2)/d), both given as 96-hour continuous intravenous infusions during weeks 1 and 4 of

36 Treatment with AEOL 10113 (continuous intravenous infusion) during 100% oxygen expo

37 romuscular-blocking agent be administered by continuous intravenous infusion early in the course of a

38 The schedule consisted of a 2-week continuous, intravenous infusion followed by a 2-week re

39 -15 at a dose of 20 mug/kg/d administered by continuous intravenous infusion for 10 days resulted in

40 Study medication was administered as a continuous intravenous infusion for 168 hrs.

41 GKI (intervention) or saline (control) as a continuous intravenous infusion for 24 h.

42 Tacrolimus monotherapy was administered via continuous intravenous infusion for 28 days then tapered

43 natumomab consolidation (up to 28 mug/day by continuous intravenous infusion for 28 days, given every

44 R75231 was given to the animals by continuous intravenous infusion for 30 min before ischem

45 and etoposide (60 mg/m(2) per day) (CDE) by continuous intravenous infusion for 4 days (96 hours) ev

46 Treatment included FU 200 mg/m2/d via continuous intravenous infusion for 4 weeks followed by

47 2 weeks, and 1200 mg/m(2) 5-FU per day as a continuous intravenous infusion for 48 h every 2 weeks.

48 olus injection administered over 5-20 min or continuous intravenous infusion for 6-96 h on day 1 of e

49 chemotherapy (cytarabine 100 mg/m(2) per day continuous intravenous infusion for 7 days plus intraven

50 eated with 2-CdA at a dose of 0.1 mg/kg/d by continuous intravenous infusion for 7 days.

51 at 0.087 or 0.1 mg/kg body weight per day by continuous intravenous infusion for 7 days.

52 w plasma stability of apelin-13 necessitates continuous intravenous infusion for therapeutic use.

53 nation with phenylbutyrate administered as a continuous intravenous infusion for varying dose and dur

54 Starting doses were 50 mg/m(2) per day as a continuous intravenous infusion from day 1 to day 4 (96

55 y 5 for prednisone; 0.4 mg/m(2) per day as a continuous intravenous infusion from day 1 to day 4 (96

56 or cyclophosphamide; 10 mg/m(2) per day as a continuous intravenous infusion from day 1 to day 4 (96

57 lowed if institutional or local standard) by continuous intravenous infusion from day 1 to day 7 and

58 n SAMe (150 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels rea

59 doses ranging from 3 to 7 mg/kg/d as a 5-day continuous intravenous infusion in cycle 1 and as a 7-da

60 travenous infusion in cycle 1 and as a 7-day continuous intravenous infusion in subsequent cycles eve

61 ian of 15 courses every 3 weeks as a 48-72 h continuous intravenous infusion (in 22 cases), with mesn

62 The observation that IL-15 administered by continuous intravenous infusion is able to induce marked

63 Terlipressin given by continuous intravenous infusion is better tolerated than

64 a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion, is active in high-risk,

65 ous injection lorazepam (group A, n = 50) or continuous intravenous infusion midazolam (group B, n =

66 Unlike continuous intravenous infusions, neurotoxicity was not

67 Simultaneously, a continuous intravenous infusion of (1)(3)C-leucine and (

68 l artery occlusion and treated with either a continuous intravenous infusion of 0.9% saline or 3% hyp

69 /kg of midazolam over 15 mins, followed by a continuous intravenous infusion of 100 microg/kg/hr (n =

70 A continuous intravenous infusion of 5% glucose providing

71 lvic external beam radiotherapy (45 Gy) with continuous intravenous infusion of 5-fluorouracil and/or

72 tions comparable to those following low-dose continuous intravenous infusion of 5-FU.

73 ratios were determined in rats treated with continuous intravenous infusion of 7.5% hypertonic salin

74 MCE was performed by continuous intravenous infusion of a nitrogen-filled bil

75 rtery, FFRic), and 2 FFR measurements during continuous intravenous infusion of adenosine (140 mug/kg

76 ion, MBV and MFV were measured by CEU during continuous intravenous infusion of albumin microbubbles

77 The preoperative treatment plan consisted of continuous intravenous infusion of cisplatin and 5-FU an

78 Continuous intravenous infusion of EGFR-AS (2 mg/kg) dec

79 s were randomly assigned to receive a 20-min continuous intravenous infusion of either PACAP-38 (10 p

80 Three-day continuous intravenous infusion of either placebo or 1 o

81 e) by intravenous bolus, followed by a 72-hr continuous intravenous infusion of either rhIL-1ra (2.0

82 tients with acute heart failure to receive a continuous intravenous infusion of either ularitide at a

83 nter open trial comparing the effects of the continuous intravenous infusion of epoprostenol (formerl

84 Recently, continuous intravenous infusion of epoprostenol has been

85 As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced

86 tin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg

87 ere randomized to receive either a low-dose, continuous intravenous infusion of iloprost (0.075 micro

88 After 60 mins, animals received either a continuous intravenous infusion of iloprost at 0.075 mic

89 and [15N]urea was determined after a primed continuous intravenous infusion of L-[15N]arginine (40 m

90 Continuous intravenous infusion of L-[4,4,5,5-(2)H(4)]-l

91 leucine metabolism postabsorptively using a continuous intravenous infusion of L-[C2H3, 1-(13)C]meth

92 instrumented Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1)

93 rumented male Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1)

94 bly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in

95 dial NO synthase levels without the need for continuous intravenous infusion of NO donors and without

96 eated in a blinded randomized fashion with a continuous intravenous infusion of normal saline, 3% hyp

97 fail to improve on calcium channel blockers, continuous intravenous infusion of PGI2 improves surviva

98 Subjects received a continuous intravenous infusion of placebo or rTFPI at 0

99 Continuous intravenous infusion of prostacyclin is an ef

100 and women in the baseline state and during a continuous intravenous infusion of recombinant human ins

101 A 72-hr, continuous intravenous infusion of rhIL-1ra failed to de

102 Continuous intravenous infusion of rTAP (average dose, 1

103 Animals in the 28-day time point received continuous intravenous infusion of rTFPI or control solu

104 n images (Agilent 5500) were obtained during continuous intravenous infusion of the contrast agent De

105 A 12-mg/h continuous intravenous infusion of TRV-027 for 5 days or

106 ptor agonist desmopressin (1 nmol.kg(-1)) or continuous intravenous infusions of arginine vasopressin

107 monary hypertension of the newborn receiving continuous intravenous infusions of morphine sulfate and

108 Oral administration, but not continuous intravenous infusion, of sirolimus (SRL) in c

109 every 3 weeks, plus 800 mg/m(2) 5-FU per day continuous intravenous infusion on days 1-5 every 3 week

110 or patients aged >60 years], plus cytarabine continuous intravenous infusion on days 1-7 [100 mg/m(2)

111 (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluse

112 it has a low oral availability and requires continuous intravenous infusion or multiple gram doses t

113 In animal models, heparin delivered as a continuous intravenous infusion or via frequent (BID) su

114 linatumomab (n = 54; 15 ug/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54

115 g/m(2) by intravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubi

116 on days 1 and 8 and ISIS-2503 6 mg/kg/d as a continuous intravenous infusion over 14 days of an every

117 roups of animals of each genotype received a continuous intravenous infusion over 30 min of phenyleth

118 e first 7 days and 28 mug/day thereafter) by continuous intravenous infusion over 4 weeks every 6 wee

119 2400 mg/m(2), administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and

120 AEG35156 was administered by continuous intravenous infusion over 7 days (7DI) or 3 d

121 ramine, and cimetidine and then treated with continuous intravenous infusion paclitaxel over 24 hours

122 nts were randomly assigned to receive either continuous intravenous infusion (TERLI-INF group) at the

123 Mean time to FFR was 100 +/- 27 s for continuous intravenous infusion versus 23 +/- 14 s for i

124 ompare the administration of terlipressin as continuous intravenous infusion versus intravenous bolus

125 h prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated ev

126 h prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated ev

127 a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion would achieve serum conc